RESEARCH TRIANGLE PARK, N.C., June 16, 2026
Simulations Plus, a global leader in model-informed and AI-accelerated drug development software, has announced that it has entered into a definitive agreement to be acquired by healthcare-focused investment firm Altaris in an all-cash transaction valued at approximately $375 million. The acquisition marks a significant development in the life sciences technology sector and is expected to strengthen Simulations Plus’ position in the rapidly evolving pharmaceutical software market. Under the terms of the agreement, Simulations Plus shareholders will receive $18.50 per share in cash, representing a 26% premium to the company’s 60-day volume-weighted average share price. Following completion of the transaction, Altaris intends to combine Simulations Plus with Chemical Computing Group (CCG), a leading provider of molecular design software, creating a more comprehensive platform serving pharmaceutical, biotechnology, chemical, and materials science organizations. The transaction highlights increasing consolidation within the healthcare technology industry as organizations seek to integrate artificial intelligence, predictive modeling, computational chemistry, and cloud-based technologies into unified drug development ecosystems.
Acquisition Creates Expanded AI-Driven Drug Development Platform
The planned combination of Simulations Plus and Chemical Computing Group is expected to create a powerful technology platform spanning the entire drug discovery and development continuum. Simulations Plus has built a strong reputation for providing advanced modeling, simulation, pharmacokinetic analysis, and regulatory science solutions that help pharmaceutical companies accelerate the development of new medicines. Chemical Computing Group complements these capabilities through its expertise in molecular modeling, computational chemistry, and structure-based drug design technologies.
Together, the organizations are expected to offer integrated software and scientific solutions that support researchers from early-stage molecular discovery through clinical development and commercialization. Industry experts view the merger as a strategic response to growing demand for AI-enabled research tools capable of improving development efficiency, reducing costs, and increasing the probability of clinical success across pharmaceutical pipelines.
Shareholders Receive Premium Value Through All-Cash Transaction
Advertisement
Under the agreement, Simulations Plus shareholders will receive $18.50 per share in cash, delivering immediate value and a significant premium relative to recent trading levels. The transaction was unanimously approved by the company’s Board of Directors and is expected to close during the fourth quarter of calendar year 2026, subject to shareholder approval, regulatory clearances, and customary closing conditions. The acquisition will be financed through a combination of committed equity and debt financing arranged by Altaris.
Once completed, Simulations Plus will become a privately held subsidiary of Altaris and will no longer trade on the Nasdaq Stock Market. Importantly, the company’s headquarters are expected to remain in Research Triangle Park, North Carolina, preserving its role as a major innovation hub within the life sciences technology industry.
Strategic Growth Opportunity for Healthcare Technology Innovation
The acquisition reflects broader trends driving transformation across the pharmaceutical and biotechnology sectors. As drug developers increasingly adopt AI-powered platforms, cloud-based infrastructure, predictive analytics, and model-informed development strategies, demand for integrated software ecosystems continues to grow. Simulations Plus has positioned itself at the forefront of this shift by providing technologies that accelerate discovery, optimize clinical trial design, support regulatory submissions, and improve commercialization outcomes. Altaris believes that combining Simulations Plus with Chemical Computing Group will create a stronger organization capable of delivering enhanced value to customers while accelerating innovation across product offerings.
The transaction underscores the strategic importance of digital technologies in modern drug development and demonstrates continued investor confidence in companies enabling next-generation pharmaceutical research. As healthcare organizations seek faster, more efficient pathways to bring therapies to market, integrated AI-driven platforms are expected to play an increasingly critical role in shaping the future of biopharmaceutical innovation.
Source: Simulations Plus press release
